96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22765 | Non-metastatic breast cancer, at the end of active treatment | Isabelle Merckaert | Breast | ULB-Erasme | Intervention de groupe sur la régulation émotionnelle | Trial closed | Improving the regulation of anxiety and fear of recurrence at the end of breast cancer treatment: A randomized study assessing the impact of a multi-component psychological group intervention | isabelle.merckaert@hubruxelles.be | |||
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 22833 | Hormono positif, Her2 negatif | Andrea Gombos | Breast | UZ-K.U.Leuven | IPSOC-mamma | Trial closed for recruitment | Prospective, Non-interventional, non-controlled multicenter observational study to evaluate aspects of pharmaceutical care and the treatment of postmenopausal patients with hormone-receptor positive, HER2-receptor negative, advanced breast cancer treated with everolimus and exemestane | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22769 | Triple negative. Metastatic. 1s Line | Andrea Gombos | Breast | MSD (Merck Sharp & Dohme) | KEYNOTE-355 | Trial closed | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355) | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22714 | ER+/HER2-. Stage III. cT1c-2 (>2cm). N1-2 or T3-4N0-2. Neoadjuvant | Andrea Gombos | Breast | Merck | KEYNOTE-756 | Trial closed for recruitment | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756) | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 29194 | Andrea Gombos | Breast | Roche | lidERA | Trial closed for recruitment | A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, her2-negative early breast cancer. | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 22660 | 3rd to 5th line, FISH+ (IHC ++/+++), prior trastu/pertu &TDM1 | Philippe Aftimos | Breast | Merus | MCLA-128-CL02 | Trial closed | Phase 2 study of MCLA-128-CL02 Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 28577 | Martine Piccart | Breast | EORTC | MINDACT | Trial closed | Dissecting the pathways of endrocrine and chemotherapy resistance in breast cancer : A translational research project of the EORTC 10041/BIG 3-04 Mindact clinical trial (1550-BCG) | martine.piccart@hubruxelles.be | ||||
| 22815 | Recurrent or persistent or metastatic tumor | Ahmad Hussein Awada | Multiple | MSD (Merck Sharp & Dohme) | MK-3475-012 | Trial closed | A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22747 | ER+/HER2-. Metastatic. Pre-menopausal | Andrea Gombos | Breast | Novartis | MONALEESA-7 | Trial closed | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22753 | HR+/HER2- | Ahmad Hussein Awada | Breast | Lilly | MONARCH3 I3Y-MC-JPBM | Trial closed | A randomized, double-blind, placebo-controlled, phase 3 study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 22724 | ER+/HER2-. Adjuvant. Pre or post menopausal | Andrea Gombos | Breast | Novartis | NATALEE | Trial closed for recruitment | A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE) (CLEE011O12301C (TRIO033)) |
accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22630 | ER+/HER2-. Neoadjuvant. Palbociclib | Michail Ignatiadis | Breast | Institut Jules Bordet | NEORHEA | Trial closed | Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 22689 | 2nd line metastatic, RECIST 1.1, HER2 negative, Hormono positive | Andrea Gombos | Breast | Odonate | ODO-TE-B301, CONTESSA | Trial closed | A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane | accueil.oncologie@hubruxelles.be | 3 | 3 |